MIRA INFORM REPORT

 

 

Report Date :

24.12.2012

 

IDENTIFICATION DETAILS

 

Name :

PHARMINTER C.V.

 

 

Registered Office :

Kabelweg 37 1014BA Amsterdam

 

 

Country :

Netherlands

 

 

Date of Incorporation :

12.04.2005

 

 

Com. Reg. No.:

34225055

 

 

Legal Form :

Commanditaire Vennootschap

 

 

Line of Business :

Wholesale of pharmaceutical goods

 

 

No. of Employees :

Not Available

 

RATING & COMMENTS

 

MIRA’s Rating :

B

 

RATING

STATUS

PROPOSED CREDIT LINE

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

Small

 

Status :

Moderate

 

 

Payment Behaviour :

Slow but Correct

 

 

Litigation :

Clear

 

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – June 30th, 2012

 

Country Name

Previous Rating

(31.03.2012)

Current Rating

(30.06.2012)

Netherlands

A1

A1

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

 

Netherlands - ECONOMIC OVERVIEW

 

The Dutch economy is the fifth-largest economy in the euro-zone and is noted for its stable industrial relations, moderate unemployment and inflation, a sizable trade surplus, and an important role as a European transportation hub. Industrial activity is predominantly in food processing, chemicals, petroleum refining, and electrical machinery. A highly mechanized agricultural sector employs only 2% of the labor force but provides large surpluses for the food-processing industry and for exports. The Netherlands, along with 11 of its EU partners, began circulating the euro currency on 1 January 2002. After 26 years of uninterrupted economic growth, the Dutch economy - highly dependent on an international financial sector and international trade - contracted by 3.5% in 2009 as a result of the global financial crisis. The Dutch financial sector suffered, due in part to the high exposure of some Dutch banks to U.S. mortgage-backed securities. In 2008, the government nationalized two banks and injected billions of dollars of capital into other financial institutions, to prevent further deterioration of a crucial sector. The government also sought to boost the domestic economy by accelerating infrastructure programs, offering corporate tax breaks for employers to retain workers, and expanding export credit facilities. The stimulus programs and bank bailouts, however, resulted in a government budget deficit of 5.3% of GDP in 2010 that contrasted sharply with a surplus of 0.7% in 2008. The government of Prime Minister Mark RUTTE began implementing fiscal consolidation measures in early 2011, mainly reductions in expenditures, which resulted in an improved budget deficit of 3.8% of GDP.

 

Source : CIA

 

 

 

CONTACTINFORMATION    

 

Company name

PHARMINTER C.V.

Tradename

Pharminter C.V.

Address

Kabelweg 37

 

1014BA Amsterdam

 

Netherlands

Mail address

Kabelweg 37

 

1014BA Amsterdam

 

Netherlands

Telephone number

0205814045

Telefax number

0205814055

E-mail address

unknown

Website

unknown

VAT number / RSIN

814770605

 

 

COMPANY INFORMATION  

 

Handelsregisternummer

34225055

Registered in

Chamber of commerce Amsterdam

Date of constitution

12-04-2005

Legal form

Commanditaire Vennootschap

Commanditair capital

0

 

 

NACE-code                               Wholesale of pharmaceutical goods (51461)

SBI-code                                  Wholesale of pharmaceutical goods (46461)

 

 

Formal objective                       De groothandel in halffabrikaten voor de farmaceutische industrie

Bank                                        Fortis Bank (Netherlands) NV

ABN Amro Bank NV

 

 

MANAGEMENT

    

Management

Foundation Nederberg

 

Kabelweg 37

 

1014BA AMSTERDAM

 

Netherlands

 

KvK: 34223636

 

Authorization: Unlimited authorization

 

Position: Partner

 

Date appointed: 12-04-2005

 

 

MANAGEMENT

 

Management                             Foundation Nederberg

Kabelweg 37

1014BA AMSTERDAM

Netherlands

KvK: 34223636

Authorization: Unlimited authorization

Position: Partner

Date appointed: 12-04-2005

 

 

PAYMENT INFORMATION

 

Payment experiences                Payments are slightly delayed

 

 

FINANCIAL INFORMATION

 

Annual accounts                        The company is not obligated to publish its financial account.

 

Tendency                                  Not to be judged because of the absence of sufficient financial information

Profitability                               Not to be judged

Solvency                                  Not to be judged

Liquidity                                    Limited based on negative payment experiences

 

Currency                                   Euro

 

 

Company structure

 

•       Pharminter C.V. (34225055) Amsterdam

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.55.08

UK Pound

1

Rs.89.53

Euro

1

Rs.72.77

 

INFORMATION DETAILS

 

Report Prepared by :

SDA

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.